Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases (Q43022187)

12 November 2017

Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases (English)

1 reference

12 November 2017

0 references

1

Anna Niwińska

1 reference

12 November 2017

Magdalena Murawska

2

1 reference

PubMed ID

20549816

12 November 2017

Katarzyna Pogoda

series ordinal

3

1 reference

PubMed ID

20549816

12 November 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

12 November 2017

1 reference

12 November 2017

116

1 reference

12 November 2017

18

1 reference

12 November 2017

4238-4247

1 reference

Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials

12 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

CNS metastases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Response of brain metastases from breast cancer to systemic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Diagnosis and management of brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Breast cancer subtypes and survival in patients with brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Breast cancer leptomeningeal metastasis--the role of multimodality treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Combination therapy with platinum and etoposide of brain metastases from breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Dramatic regression of multiple brain metastases from breast cancer with Capecitabine: another arrow at the bow?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Capecitabine therapy of central nervous system metastases from breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Extended survival in women with brain metastases from HER2 overexpressing breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Survival in patients with brain metastases from breast cancer: the importance of HER-2 status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25391

7 January 2021

Identifiers

DOI

10.1002/CNCR.25391

1 reference

12 November 2017

1 reference

PubMed ID

20549816